Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Nitrogen containing other than solely as a nitrogen in an...
Reexamination Certificate
2001-04-10
2003-08-26
Low, Christopher S. F. (Department: 1653)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Nitrogen containing other than solely as a nitrogen in an...
C514S003100, C514S350000, C514S352000, C514S356000, C514S396000, C514S592000
Reexamination Certificate
active
06610746
ABSTRACT:
FIELD OF THE INVENTION
The present invention relates to methods of treating non-insulin dependent diabetes mellitus, insulin resistance, Syndrome X, diabetic neuropathy, diabetic nephropathy, diabetic retinopathy, diabetic cardiomyopathy, polycystic ovary syndrome, cataracts, hyperglycemia, or impaired glucose tolerance, the methods comprising the step of administering to a patient having or at risk of having non-insulin dependent diabetes mellitus, insulin resistance, Syndrome X, diabetic neuropathy, diabetic nephropathy, diabetic retinopathy, diabetic cardiomyopathy, polycystic ovary syndrome, cataracts, hyperglycemia, or impaired glucose tolerance a synergistic amount of: 1) a sulfonylurea, a non-sulfonylurea K
+
ATP channel blocker, or a sulfonylurea and a non-sulfonylurea K
+
ATP channel blocker; and 2) a cAMP phosphodiesterase type 3 inhibitor. The present invention also relates to kits and pharmaceutical compositions that comprise: 1) a sulfonylurea, a non-sulfonylurea K
+
ATP channel blocker, or a sulfonylurea and a non-sulfonylurea K
+
ATP channel blocker; and 2) a cAMP phosphodiesterase type 3 inhibitor. The present invention also relates to kits and pharmaceutical compositions that comprise: 1) a sulfonylurea, a non-sulfonylurea K
+
ATP channel blocker, or a sulfonylurea and a non-sulfonylurea K
+
ATP channel blocker; 2) a cAMP phosphodiesterase type 3 inhibitor; and 3) an additional compound useful for the treatment of non-insulin dependent diabetes mellitus, insulin resistance, Syndrome X, diabetic neuropathy, diabetic nephropathy, diabetic retinopathy, diabetic cardiomyopathy, polycystic ovary syndrome, cataracts, hyperglycemia, or impaired glucose tolerance.
BACKGROUND OF THE INVENTION
In spite of the early discovery of insulin and its subsequent widespread use in the treatment of diabetes, and the later discovery of and use of sulfonylureas, biguanides and thiazolidenediones, such as troglitazone, rosiglitazone or pioglitazone, as oral hypoglycemic agents, the treatment of diabetes can be improved.
A group of compounds that stimulate insulin secretion and stimulate de novo synthesis of insulin are the cAMP phosphodiesterase type 3 inhibitors. It is believed that cAMP phosphodiesterase type 3 inhibitors act to increase insulin secretion by increasing intracellular levels of cAMP in pancreatic &bgr;-cells in the islet of Langerhans. In contrast, sulfonylureas act on the K
+
ATP channels of pancreatic &bgr;-cells in the islet of Langerhans. Moreover, cAMP phosphodiesterase type 3 is known to exist in two forms: type A and type B. Type A cAMP phosphodiesterase 3 is associated with cardiac tissue and with platelets, and type B is associated with liver and adipose tissue, and &bgr;-cells in the pancreas.
In addition to sulfonylureas, which stimulate insulin secretion by acting on the K
+
ATP channels, a group of non-sulfonylureas are known to stimulate insulin secretion by acting on K
+
ATP channels. Examples of such non-sulfonylurea insulin secretagogues include nateglinide and repaglinide.
The present invention provides an improved method of treating non-insulin dependent diabetes mellitus, insulin resistance, Syndrome X, diabetic neuropathy, diabetic nephropathy, diabetic retinopathy, diabetic cardiomyopathy, polycystic ovary syndrome, cataracts, hyperglycemia, or impaired glucose tolerance using a synergistic amount of: 1) a sulfonylurea, a non-sulfonylurea K
+
ATP channel blocker, or a sulfonylurea and a non-sulfonylurea K
+
ATP channel blocker; and 2) a cAMP phosphodiesterase type 3 inhibitor.
The present invention also relates to kits and pharmaceutical compositions that comprise: 1) a sulfonylurea, a non-sulfonylurea K
+
ATP channel blocker, or a sulfonylurea and a non-sulfonylurea K
+
ATP channel blocker; and 2) a cAMP phosphodiesterase type 3 inhibitor.
In addition, the present invention relates to kits and pharmaceutical compositions that comprise: 1) a sulfonylurea, a non-sulfonylurea K
+
ATP channel blocker, or a sulfonylurea and a non-sulfonylurea K
+
ATP channel blocker; 2) a cAMP phosphodiesterase type 3 inhibitor; and 3) an additional compound useful for the treatment of non-insulin dependent diabetes mellitus, insulin resistance, Syndrome X, diabetic neuropathy, diabetic nephropathy, diabetic retinopathy, diabetic cardiomyopathy, polycystic ovary syndrome, cataracts, hyperglycemia, or impaired glucose tolerance.
SUMMARY OF THE INVENTION
The present invention provides methods of treating non-insulin dependent diabetes mellitus, the methods comprising the step of administering to a patient having or at risk of having non-insulin dependent diabetes a synergistic amount of: 1) a sulfonylurea, a non-sulfonylurea K
+
ATP channel blocker, or a sulfonylurea and a non-sulfonylurea K
+
ATP channel blocker; and 2) a cAMP phosphodiesterase type 3 inhibitor.
Also provided are methods of treating insulin resistance, the methods comprising the step of administering to a patient having or at risk of having insulin resistance a synergistic amount of: 1) a sulfonylurea, a non-sulfonylurea K
+
ATP channel blocker, or a sulfonylurea and a non-sulfonylurea K
+
ATP channel blocker; and 2) a cAMP phosphodiesterase type 3 inhibitor.
Also provided are methods of treating Syndrome X, the methods comprising the step of administering to a patient having or at risk of having Syndrome X a synergistic amount of: 1) a sulfonylurea, a non-sulfonylurea K
+
ATP channel blocker, or a sulfonylurea and a non-sulfonylurea K
+
ATP channel blocker; and 2) a cAMP phosphodiesterase type 3 inhibitor.
Also provided are methods of treating diabetic neuropathy, diabetic nephropathy, diabetic retinopathy, diabetic cardiomyopathy, polycystic ovary syndrome, or cataracts, the methods comprising the step of administering to a patient having or at risk of having diabetic neuropathy, diabetic nephropathy, diabetic retinopathy, diabetic cardiomyopathy, polycystic ovary syndrome, or cataracts a synergistic amount of: 1) a sulfonylurea, a non-sulfonylurea K
+
ATP channel blocker, or a sulfonylurea and a non-sulfonylurea K
+
ATP channel blocker; and 2) a cAMP phosphodiesterase type 3 inhibitor.
Also provided are methods of treating hyperglycemia, the methods comprising the step of administering to a patient having or at risk of having hyperglycemia a synergistic amount of: 1) a sulfonylurea, a non-sulfonylurea K
+
ATP channel blocker, or a sulfonylurea and a non-sulfonylurea K
+
ATP channel blocker; and 2) a cAMP phosphodiesterase type 3 inhibitor.
Also provided are methods of treating impaired glucose tolerance, the methods comprising the step of administering to a patient having or at risk of having impaired glucose tolerance a synergistic amount of: 1) a sulfonylurea, a non-sulfonylurea K
+
ATP channel blocker, or a sulfonylurea and a non-sulfonylurea K
+
ATP channel blocker; and 2) a cAMP phosphodiesterase type 3 inhibitor.
Also provided are pharmaceutical compositions comprising a sulfonylurea and/or non-sulfonylurea K
+
ATP channel blocker, and a cAMP phosphodiesterase type 3 inhibitor.
Also provided are pharmaceutical compositions comprising a sulfonylurea and a cAMP phosphodiesterase type 3 inhibitor.
Also provided are pharmaceutical compositions comprising a non-sulfonylurea K
+
ATP channel blocker and a cAMP phosphodiesterase type 3 inhibitor.
Also provided are pharmaceutical compositions comprising a sulfonylurea, a non-sulfonylurea K
+
ATP channel blocker, and a cAMP phosphodiesterase type 3 inhibitor.
Also provided are kits for the treatment of non-insulin dependent diabetes mellitus, the kits comprising:
a) a first pharmaceutical composition comprising: 1) a sulfonylurea, a non-sulfonylurea K
+
ATP channel blocker, or a sulfonylurea and a non-sulfonylurea K
+
ATP channel blocker; and 2) a cAMP phosphodiesterase type 3 inhibitor;
b) a second pharmaceutical composition comprising a second compound useful
Fryburg David A.
Parker Janice C.
Benson Gregg C.
Goddard Carl J.
Kam Chih-Min
Low Christopher S. F.
Pfizer Inc.
LandOfFree
Synergistic effect of a sulfonylurea and/or non-sulfonylurea... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Synergistic effect of a sulfonylurea and/or non-sulfonylurea..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Synergistic effect of a sulfonylurea and/or non-sulfonylurea... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3086392